![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Intuitive Investments Group Plc | LSE:IIG | London | Ordinary Share | GB00BPTH6Y20 | ORD GBP0.1 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 141.50 | 140.00 | 143.00 | 142.00 | 141.50 | 141.50 | 16,003 | 08:00:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investors, Nec | -2.45M | -3.24M | -0.0160 | -88.44 | 286.24M |
TIDMIIG
RNS Number : 0009V
Intuitive Investments Group plc
05 August 2022
5 August 2022
Intuitive Investments Group plc
("IIG" or the "Company")
Investment in PneumoWave Limited
Intuitive Investments Group plc (AIM: IIG), a closed-end life sciences investment company which owns the entirety of Sanondaf, a specialist disinfection and hygiene services business, has invested a further GBP100,000 into existing portfolio company PneumoWave Limited ("PneumoWave"), formerly known as Altair Medical. This equity investment is a bridge, by way of advance subscription agreement, to a Series A round of circa GBP7.5 million, which PneumoWave is looking to close in October 2022. IIG has previously invested GBP350,000 in PneumoWave, representing a 6.55 per cent. interest in PneumoWave's issued share capital.
PneumoWave is developing a biosensor and real time analysis platform that provides fully automated data capture, analysis, notification and response management for serious respiratory events that require rapid response. Its focus initially is on opioid induced respiratory depression, now the leading cause of accidental death in most developed countries and which claimed the lives of approximately 80,000 in the US and UK in 2021 alone.
The technology is being developed by clinicians to ensure maximum uptake across the diverse range of patient groups affected by inadvertent overdose, in hospitals and at home, from both therapeutic and illicit opioids. PneumoWave deploys proprietary algorithms and artificial intelligence on the clinical datasets to identify digital bio markers with predictive and preventive potential.
In 2020, PneumoWave was awarded the Breakthrough Medical Device designation from the U.S. Food and Drug Administration and is targeting Class 2 clearance in the US via the De Novo pathway in the first quarter of 2024. PneumoWave has also achieved Class 1 UK Conformity Assessed clearance.
PneumoWave has three opioid-focused clinical trials underway, having identified digital biomarkers for opioid overdose, it is aiming to prevent deaths in clinical trials in the first half of 2023. A further seven clinical trials are in process or due to start before the end of 2022.
Additional information relating to PneumoWave can be found at: https://pneumowave.com/
Stewart White, Chairman of IIG's Advisory Panel, is a Non-executive Director of PneumoWave.
For further information, please contact:
Intuitive Investments Group plc www.iigplc.com Julian Baines, Non-Executive Chairman Via Walbrook PR Robert Naylor, CEO SP Angel Corporate Finance LLP - Nominated Adviser +44 (0) 20 3470 0470 Jeff Keating / David Hignell / Kasia Brzozowska Turner Pope Investments (TPI) Ltd - Broker +44 (0) 20 3657 0050 Andrew Thacker / James Pope Walbrook PR Limited - Media & Investor +44 (0)20 7933 8780 or intuitive@walbrookpr.com Relations +44 (0) 7980 541 893 / +44 (0) Paul McManus/ Sam Allen 7502 558 258
About Intuitive Investments Group plc
The Company is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the chairman of the Investment Committee, David Evans, to seek to generate capital growth over the long term for shareholders.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCBKQBDABKDFFK
(END) Dow Jones Newswires
August 05, 2022 02:00 ET (06:00 GMT)
1 Year Intuitive Investments Chart |
1 Month Intuitive Investments Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions